OPEN APP
Home / News / Bharat Biotech launches first batch of Covaxin from its Ankleshwar facility

NEW DELHI : Vaccine manufacturer Bharat Biotech on Sunday announced the commercial launch of the first batch of its covid-19 vaccine Covaxin from its Chiron Behring facility in Ankleshwar, Gujarat.  

 

A new filing facility constructed during 2020 is now being utilized for the production of Covaxin. The production had started in early June before which the team had executed engineering batches to study the equipment functionality at the facility. Chiron Behring Vaccines is a wholly-owned subsidiary of Hyderabad-based pharma company Bharat Biotech.  Product manufactured from Ankleshwar facilities will be available for supplies starting September 2021, the company said.

“We want to ensure that Bharat Biotech can ably meet the demand for Covaxin such that individuals across the country, and the globe, have access to the vaccine and can secure their health and safety. Our goal to develop a vaccine with global safety and efficacy standards has now been achieved, we are now marching towards the goal of annualized capacity of 1.0 billion doses," Dr. Krishna Ella, chairman & managing director, Bharat Biotech, said. 

 

The company has already deployed multiple production lines at its Hyderabad, Malur, Bengaluru, and Pune campuses, and the addition of Chiron Behring, Ankleshwar will further augment its covaxin production capacity. 

“India is focused on slowing the spread of covid-19 in the country, and the key to achieving this lies in the swift and efficient administration of vaccines. We want to ensure equitable access of the vaccine to every Indian citizen, and the expansion of covaxin production facilities by Bharat Biotech will take us closer to this goal," Union minister of health and family welfare Mansukh Mandaviya said who inaugurated the Covaxin batches.   

Bharat Biotech is also exploring manufacturing partnerships with its partners in other countries, who have prior expertise with commercial scale manufacturing of inactivated viral vaccines under biosafety containment for further augmentation.    

“Our efforts over the last one year have fructified, and we are now several steps closer to achieving our goal of providing covaxin to all pockets of the country and overseas. The pandemic has impacted people across the globe, and it is only through collaborative efforts that we can hope to mitigate its spread and impact," Suchitra Ella, joint managing director, Bharat Biotech, said. 

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint. Download our App Now!!

Close
×
Edit Profile
My ReadsRedeem a Gift CardLogout